Literature DB >> 25679763

Degradation of AMPK by a cancer-specific ubiquitin ligase.

Carlos T Pineda1, Saumya Ramanathan1, Klementina Fon Tacer1, Jenny L Weon1, Malia B Potts2, Yi-Hung Ou2, Michael A White2, Patrick Ryan Potts3.   

Abstract

AMP-activated protein kinase (AMPK) is a master sensor and regulator of cellular energy status. Upon metabolic stress, AMPK suppresses anabolic and promotes catabolic processes to regain energy homeostasis. Cancer cells can occasionally suppress the growth-restrictive AMPK pathway by mutation of an upstream regulatory kinase. Here, we describe a widespread mechanism to suppress AMPK through its ubiquitination and degradation by the cancer-specific MAGE-A3/6-TRIM28 ubiquitin ligase. MAGE-A3 and MAGE-A6 are highly similar proteins normally expressed only in the male germline but frequently re-activated in human cancers. MAGE-A3/6 are necessary for cancer cell viability and are sufficient to drive tumorigenic properties of non-cancerous cells. Screening for targets of MAGE-A3/6-TRIM28 revealed that it ubiquitinates and degrades AMPKα1. This leads to inhibition of autophagy, activation of mTOR signaling, and hypersensitization to AMPK agonists, such as metformin. These findings elucidate a germline mechanism commonly hijacked in cancer to suppress AMPK.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25679763      PMCID: PMC5629913          DOI: 10.1016/j.cell.2015.01.034

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  62 in total

1.  Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase.

Authors:  Marianne Suter; Uwe Riek; Roland Tuerk; Uwe Schlattner; Theo Wallimann; Dietbert Neumann
Journal:  J Biol Chem       Date:  2006-08-30       Impact factor: 5.157

2.  Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

Authors:  Sirwan Hadad; Takayuki Iwamoto; Lee Jordan; Colin Purdie; Susan Bray; Lee Baker; Gera Jellema; Steve Deharo; D Grahame Hardie; Lajos Pusztai; Stacy Moulder-Thompson; John A Dewar; Alastair M Thompson
Journal:  Breast Cancer Res Treat       Date:  2011-06-08       Impact factor: 4.872

3.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Authors:  Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

Review 4.  Metformin--mode of action and clinical implications for diabetes and cancer.

Authors:  Ida Pernicova; Márta Korbonits
Journal:  Nat Rev Endocrinol       Date:  2014-01-07       Impact factor: 43.330

Review 5.  When MAGE meets RING: insights into biological functions of MAGE proteins.

Authors:  Yue Feng; Jinlan Gao; Maojun Yang
Journal:  Protein Cell       Date:  2011-02-20       Impact factor: 14.870

6.  5'-AMP-activated protein kinase (AMPK) supports the growth of aggressive experimental human breast cancer tumors.

Authors:  Keith R Laderoute; Joy M Calaoagan; Wan-Ru Chao; Dominc Dinh; Nicholas Denko; Sarah Duellman; Jessica Kalra; Xiaohe Liu; Ioanna Papandreou; Lidia Sambucetti; Laszlo G Boros
Journal:  J Biol Chem       Date:  2014-07-03       Impact factor: 5.157

7.  Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.

Authors:  Longyi Zheng; Wen Yang; Fuquan Wu; Chao Wang; Lexing Yu; Liang Tang; Bijun Qiu; Yuqiong Li; Linna Guo; Mengchao Wu; Gensheng Feng; Dajin Zou; Hongyang Wang
Journal:  Clin Cancer Res       Date:  2013-08-13       Impact factor: 12.531

8.  Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK).

Authors:  Kay Barnes; Jean C Ingram; Omar H Porras; L Felipe Barros; Emma R Hudson; Lee G D Fryer; Fabienne Foufelle; David Carling; D Grahame Hardie; Stephen A Baldwin
Journal:  J Cell Sci       Date:  2002-06-01       Impact factor: 5.285

9.  Histological evaluation of AMPK signalling in primary breast cancer.

Authors:  Sirwan M Hadad; Lee Baker; Philip R Quinlan; Katherine E Robertson; Susan E Bray; George Thomson; David Kellock; Lee B Jordan; Colin A Purdie; David G Hardie; Stewart Fleming; Alastair M Thompson
Journal:  BMC Cancer       Date:  2009-09-01       Impact factor: 4.430

10.  Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination.

Authors:  Yi-Heng Hao; Jennifer M Doyle; Saumya Ramanathan; Timothy S Gomez; Da Jia; Ming Xu; Zhijian J Chen; Daniel D Billadeau; Michael K Rosen; Patrick Ryan Potts
Journal:  Cell       Date:  2013-02-28       Impact factor: 41.582

View more
  141 in total

1.  Deubiquitination and Activation of AMPK by USP10.

Authors:  Min Deng; Xu Yang; Bo Qin; Tongzheng Liu; Haoxing Zhang; Wei Guo; Seung Baek Lee; Jung Jin Kim; Jian Yuan; Huadong Pei; Liewei Wang; Zhenkun Lou
Journal:  Mol Cell       Date:  2016-02-11       Impact factor: 17.970

2.  Pre-stroke Metformin Treatment is Neuroprotective Involving AMPK Reduction.

Authors:  Tian Deng; Yan-Rong Zheng; Wei-Wei Hou; Yang Yuan; Zhe Shen; Xiao-Li Wu; Ying Chen; Li-San Zhang; Wei-Wei Hu; Zhong Chen; Xiang-Nan Zhang
Journal:  Neurochem Res       Date:  2016-06-27       Impact factor: 3.996

3.  Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.

Authors:  Sachet A Shukla; Pavan Bachireddy; Bastian Schilling; Christina Galonska; Qian Zhan; Clyde Bango; Rupert Langer; Patrick C Lee; Daniel Gusenleitner; Derin B Keskin; Mehrtash Babadi; Arman Mohammad; Andreas Gnirke; Kendell Clement; Zachary J Cartun; Eliezer M Van Allen; Diana Miao; Ying Huang; Alexandra Snyder; Taha Merghoub; Jedd D Wolchok; Levi A Garraway; Alexander Meissner; Jeffrey S Weber; Nir Hacohen; Donna Neuberg; Patrick R Potts; George F Murphy; Christine G Lian; Dirk Schadendorf; F Stephen Hodi; Catherine J Wu
Journal:  Cell       Date:  2018-04-12       Impact factor: 41.582

Review 4.  Precision autophagy directed by receptor regulators - emerging examples within the TRIM family.

Authors:  Tomonori Kimura; Michael Mandell; Vojo Deretic
Journal:  J Cell Sci       Date:  2016-02-15       Impact factor: 5.285

5.  AMPK-dependent phosphorylation of lipid droplet protein PLIN2 triggers its degradation by CMA.

Authors:  Susmita Kaushik; Ana Maria Cuervo
Journal:  Autophagy       Date:  2016       Impact factor: 16.016

6.  A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma.

Authors:  Cheng Wang; Yayun Gu; Erbao Zhang; Kai Zhang; Na Qin; Juncheng Dai; Meng Zhu; Jia Liu; Kaipeng Xie; Yue Jiang; Xuejiang Guo; Mingxi Liu; Guangfu Jin; Hongxia Ma; Tao Jiang; Rong Yin; Yankai Xia; Li Liu; Shouyu Wang; Bin Shen; Ran Huo; Lin Xu; Jiahao Sha; Bin Qu; Hongbing Shen; Zhibin Hu
Journal:  Oncogene       Date:  2018-10-23       Impact factor: 9.867

Review 7.  Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer.

Authors:  Lu Zhang; Jerry W Shay
Journal:  J Natl Cancer Inst       Date:  2017-08-01       Impact factor: 13.506

8.  Epigenetic activation of POTE genes in ovarian cancer.

Authors:  Ashok Sharma; Mustafa Albahrani; Wa Zhang; Christina N Kufel; Smitha R James; Kunle Odunsi; David Klinkebiel; Adam R Karpf
Journal:  Epigenetics       Date:  2019-03-04       Impact factor: 4.528

9.  Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator.

Authors:  Prashant Trikha; Robert L Plews; Andrew Stiff; Shalini Gautam; Vincent Hsu; David Abood; Robert Wesolowski; Ian Landi; Xiaokui Mo; John Phay; Ching-Shih Chen; John Byrd; Michael Caligiuri; Susheela Tridandapani; William Carson
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

10.  TRIM17 contributes to autophagy of midbodies while actively sparing other targets from degradation.

Authors:  Michael A Mandell; Ashish Jain; Suresh Kumar; Moriah J Castleman; Tahira Anwar; Eeva-Liisa Eskelinen; Terje Johansen; Rytis Prekeris; Vojo Deretic
Journal:  J Cell Sci       Date:  2016-08-25       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.